Clearmind Medicine Inc. (CMND) has received a positive recommendation from its independent Data and Safety Monitoring Board to continue its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic treatment for Alcohol Use Disorder (AUD). This recommendation follows the successful completion of the third patient cohort, where the drug demonstrated a favorable safety profile with no serious adverse events reported. The trial will now progress to a fourth cohort, testing a higher dose of 160 mg.
This development is significant for the financial markets as it highlights Clearmind’s potential in a therapeutic area with limited treatment options, which could lead to increased investor interest. The positive safety data may also bolster confidence in the company’s future prospects, particularly as it seeks to validate CMND-100’s efficacy in treating AUD.
Market professionals should note that CMND’s stock has experienced volatility, closing at $0.65 and showing a slight uptick in after-hours trading. Continued positive trial results could be a catalyst for price recovery and increased trading activity.
Source: nasdaq.com